A Summary of 2018 First Quarter Highlights & Financial Results
- Q1 results support expected 2018 full year spending decrease of approximately $15M
- Sale of excess plasma inventory completed in April contributing $14M to proforma cash runway of $91M
- Clinical programs streamlined to manage costs for balance of 2018
- Continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions